April 16 (Reuters) - Q32 Bio Inc QTTB.O:
Q32 BIO DOSES FIRST PATIENTS IN BOTH PART A OPEN-LABEL EXTENSION AND PART B OF SIGNAL-AA PHASE 2A TRIAL EVALUATING BEMPIKIBART IN ALOPECIA AREATA
Q32 BIO INC - SIGNAL-AA PART B TOPLINE DATA READOUT ON-TRACK FOR 1H'26
Q32 BIO INC - EXPECTS SIGNAL-AA PART B DATA IN 1H'26
Source text: ID:nPn76h8Wya
Further company coverage: QTTB.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.